Clinical Trial Update: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) [Phase 4]

View source ↗

Summary

Phase 4 trial update showing completion of a study evaluating aprepitant to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nausea, Vomiting | Phase 4 | Status: COMPLETED